DGFI Young Immunologists’ Post

I'm pleased to share our research group's new scientific article published in Frontiers in Immunology. Tumor cells often overexpress CD47, a potent innate immune checkpoint, as a strategy to suppress the immune system and survive. When CD47 binds SIRPa receptor, it renders macrophages unable to eat cancer cells. In this report, we provide new insights into how NRF-1 transcription factor impacts CD47 regulation in cancer cells. NRF-1 appears to bind multiple CD47 promoter sites with different affinity among malignant and normal cell types leading to increased CD47 protein levels in malignant cells. https://lnkd.in/g5rG6vrB

Pancreatic ductal adenocarcinoma is one of the deadliest forms of #Cancer. Using #OrganoidPower, researchers from Philipps-Universität Marburg have gained a deeper understanding of the genetics behind #Metastatsis and disease progression 📖 Read the full study in Nature: https://okt.to/hVRcjM #ScienceForaSaferWorld

My latest article, "The molecular landscape of T cell exhaustion in the tumor microenvironment and reinvigoration strategies," has been published in the International Reviews of Immunology! This comprehensive review dives into the complex world of T cell exhaustion, exploring the molecular mechanisms behind this phenomenon and its impact on immunotherapy. We discuss the intricate interplay between the tumor microenvironment and T cells, shedding light on the distinct characteristics of pre-exhausted and exhausted T cells. Moreover, we investigate promising strategies for reversing T cell exhaustion, opening up avenues for more effective cancer treatment. Many thanks to Prof. Nima Rezaei and Dr. Alaleh Rezalotfi for their invaluable guidance. Check out the article here:https://lnkd.in/ebcTSJT9

🦠🔬 #Covid #Treatment | Clinical efficacy of XAV-19, our anti-COVID antibody, published in Frontiers in Immunology : https://lnkd.in/e47wmKyv ➡️ XENOTHERA, a Nantes (France) – based biotech, that celebrates its tenth anniversary this year, develops innovative treatments by glyco-humanized polyclonal antibodies (GH-pAb) for infectious diseases, cancer, and transplantation. Thanks to its technology, in 2020 the biotech launched XAV-19, which clinical efficacy in moderate COVID has just been published in a peer-reviewed scientific journal. 🔍 More information in our press release below. Frontiers in Immunology Research Network (FIRN)

In our recent paper, we have had an overview of the strategies involving the combination of anti-checkpoint immunotherapies and cancer vaccines for improving the clinical outcomes among cancer patients. Fortunately, this article has recently been accepted for publication in the Human Immunology, Elsevier.

Cancer remains a leading cause of death worldwide, with increasing incidence and mortality rates. Despite advancements in treatment, current strategies often negatively affect patients' quality of life. One promising future approach lies in immunology, particularly targeting the "eat me" and "Don't eat me" signals in cancer cells, which help tumors evade immune system detection. Macrophages, crucial for immune response, are inhibited by overexpressed "Don't eat me" signals like CD47 and PD-L1 in tumor cells, allowing their uncontrolled growth. By exploring therapies that manipulate these signals, a novel path for more effective cancer treatments may emerge. https://lnkd.in/dXP_F5nR

Exciting News! 🌟 Explore the Special Issue on "Tumor Microenvironment, Immunology, and Precision Medicine of Liver Cancer," guest edited by Dr. Lynn Jeanette Savic ⏰ Deadline: Mar 31, 2025 Featuring an article by Dr. Savic, "The Effects of Hypoxia on the Immune–Metabolic Interplay in Liver Cancer" Explore now: https://lnkd.in/emfCSiS8

Bio-Techne will be present at #SIICA24 6th International Conference of Translational Immunology MAY 22-25, 2024 Monopoli, ITALY Myself and Euplio Visco will be at the booth happy to discuss how we can accelerate your immunology research workflow. #biotech #cancerimmunotherapy #immunooncology #cancer #spatialbiology #multiomics #immunology

Featured article in Cancer Immunology Research: Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells Hypersialylation of tumors can result in immune escape and tumor growth. Using CRISPR to knock out the inhibitory receptor Siglec-9, as well as through studies with Siglec-9-based chimeric switch receptors (CSR) in a human tumor xenograft model, Eisenberg and colleagues showed that human T cells also experience Siglec-9/sialic acid signaling, which hinders anti-tumoral effector function. Go deeper: https://bit.ly/3YidH0q

Targeting molecular pathways to control immune checkpoint inhibitor toxicities Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment but are associated with immune-related adverse events (irAEs). A recent Trends in Immunology study examines molecular pathways to address these toxicities, aiming to improve treatment outcomes. https://lnkd.in/d38aM22M Prof. Dr. med. Jessica Hassel Robin Reschke Thomas Gajewski Ryan Sullivan Evan Lipson Harvard University Johns Hopkins Hospital UChicago Medicine #Cancer #CancerResearch #Immunotherapy #Medicine #Health #Oncology #OncoDaily